Kim C. Ohaegbulam

Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy

Élodie Picarda, Kim C. Ohaegbulam, Xingxing Zang · Clinical Cancer Research · 2016 · 547 citations

HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

Ruihua Zhao, Jordan M. Chinai, Susan Buhl et al. · Proceedings of the National Academy of Sciences · 2013 · 217 citations · Full text

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

Murali Janakiram, Jordan M. Chinai, Susan Fineberg et al. · Clinical Cancer Research · 2014 · 150 citations · Full text

Vitamin D Supplementation in COVID-19 Patients: A Clinical Case Series

Kim C. Ohaegbulam, Mohamed Swalih, Pranavkumar Patel et al. · American Journal of Therapeutics · 2020 · 108 citations · Full text

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Takeshi Yoshida, Lanxi Song, Yun Bai et al. · PLoS ONE · 2016 · 96 citations · Full text